Approved: Sorafenib and Lenvatinib for the Treatment of Progressive, RAI-Refractory DTC

In this video, Marcia S. Brose, MD, provides an overview of sorafenib and lenvatinib, the currently approved multikinase inhibitors for thyroid cancer. During her presentation, Dr. Brose analyzes the DECISION trial, which explored the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioiodine (RAI) refractory thyroid cancer, and the SELECT trial, which evaluated lenvatinib in RAI refractory differentiated thyroid cancer. Her talk involves the design, endpoints, treatment-emergent adverse events, subgroup analyses and outcomes for both studies.

View the 2015 presentation here



Related Links


August 19, 2016

Created by

Penn Physician VideoLink